Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 6Small Cell Lung Carcinoma 2Neoplasms 2Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Cancer Limited Stage 1Mesothelioma, Malignant 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiotherapy 6Cisplatin 6Sunitinib 5Carboplatin 5Paclitaxel 4Thymectomy 3130-nm albumin-bound paclitaxel 3selinexor 2lenvatinib 2fludarabine 2Taxes 2Robotic Surgical Procedures 2Ramucirumab 2Prednisone 2Pemetrexed 2Octreotide 2Nivolumab 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Imatinib Mesylate 2Etoposide 2Erlotinib Hydrochloride 2Drug Therapy 2Doxorubicin 2Chemoradiotherapy 2Celecoxib 2zimberelimab 1vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymoma × Radiation Dose Hypofractionation × Thoracic × Clear all
NCT03663764 2021-12-10

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Sun Yat-sen University

Phase 2 Unknown
57 enrolled
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡